The aim of this trial is to find a safe and effective dose of a drug called Ponatinib when used in combination with chemotherapy in patients with Chronic Myeloid Leukaemia (CML) whose disease has moved in to blast phase. Ponatinib is a Tyrosine Kinase Inhibitor (TKI) and TKIs stop enzymes called Tyrosine Kinases from working. By stopping these enzymes from working, the normal signals within the cells are disrupted. TKIs are often used in the treatment of cancers including leukaemia such as CML. 30 patients from the United Kingdom will be invited to take part in this trial.
Trial summary document [.pdf]
Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
Chief Investigator: Professor Mhairi Copland
|
|
Sponsor: University of Birmingham
|
|
Funders: Bloodwise, as part of their Trials Acceleration Programme (TAP) and Ariad Pharmaceuticals Inc.
|
|
Disease Site: Chronic myeloid leukaemia
|
|
Trial Type: Clinical Trial of an Investigational Medicinal Product
|
|
Status: Closed to recruitment, in follow up
|
|
UKCRN Study ID: 15879
|
|
| Open to new sites? No |
|
Recruitment start date: 02-Dec-2014
|
|
Recruitment end date: 26-Apr-2018
|
|
CRCTU Trial Management Team: Haematology
|
|
Trial E-mail Address: Matchpoint@trials.bham.ac.uk
|
|